Search

The impact of positive airway pressure (PAP) therapy for OSA on health care costs is uncertain. Are 3-year health care costs associated with PAP adherence in participants from the Tele-OSA clinical trial? Participants with OSA and prescribed PAP in the Tele-OSA study were stratified into three PAP adherence groups based on usage patterns over 3 years: (1) high (consistently ≥ 4 h/night), (2) moderate (2-3.9 h/night or inconsistently ≥ 4 h/night), and (3) low (< 2 h/night). Using data from 3 months of the Tele-OSA trial and 33 months of posttrial follow up, average health care costs (2020 US dollars) in 6-month intervals were derived from electronic health records and analyzed using multivariable generalized linear models. Of 543 participants, 25% were categorized as having high adherence, 22% were categorized as having moderate adherence, and 52% were categorized as having low adherence to PAP therapy. Average PAP use mean ± SD was 6.5 ± 1.0 h, 3.7 ± 1.2 h, and 0.5 ± 0.5 h for the high, moderate, and low adherence groups, respectively. The high adherence group had the lowest average covariate-adjusted 6-month health care costs ± SE ($3,207 ± $251) compared with the moderate ($3,638 ± $363) and low ($4,040 ± $304) adherence groups. Significant cost differences were observed between the high and low adherence groups ($832; 95% CI, $127 to $1,538); differences between moderate and low adherence were nonsignificant ($401; 95% CI, −$441 to $1,243). In participants with OSA, better PAP adherence was associated with significantly lower health care costs over 3 years. Findings support the importance of strategies to enhance long-term PAP adherence. [Display omitted] [ABSTRACT FROM AUTHOR]

Objective: Obstructive sleep apnea (OSA) is a serious medical condition that adds to patient morbidity and mortality. Treatment with positive airway pressure (PAP) is the standard of care, but many patients refuse or do not tolerate PAP. Little is known about the subsequent management of these patients. We sought to understand what types of treatment, if any, adult patients with OSA receive who either fail or refuse PAP therapy within our institution.Study Design: Retrospective chart review.Setting: Academic hospital.Subjects: All adult patients undergoing polysomnogram during the months of March and April 2010 (n = 1174) who were diagnosed with OSA.Methods: The electronic medical record was reviewed to determine the subsequent management of patients with a diagnosis of OSA, including tolerance or failure of PAP and referral to specialists upon intolerance.Results: Of 1174 patients, 616 met inclusion criteria. Ultimately, 260 (42%) had documented adherence to PAP. Of 241 untreated patients, 84 patients (35%) were referred for further attempts at management of diagnosed OSA. Nearly half of patients with diagnosed OSA did not have continued treatment or referral.Conclusion: To our knowledge, this is the first study to define the subsequent management of patients who have failed or refused PAP. Despite the known sequelae of OSA, clinicians are not treating a significant percentage of patients with diagnosed OSA. Those who fail to tolerate PAP therapy are unlikely to be referred for additional treatment. Therapies other than PAP may be warranted in this population. [ABSTRACT FROM AUTHOR]